New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs

In a recent study posted to the bioRxiv* pre-print server, researchers tested three next-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) inhibitors, that is, nirmatrelvir, ensitrelvir, and FB2001, using a novel cell-based assay.

Study: Rapid resistance profiling of SARS-CoV-2 protease inhibitors. Image Credit: Kateryna Kon/Shutterstock
Study: Rapid resistance profiling of SARS-CoV-2 protease inhibitors. Image Credit: Kateryna Kon/Shutterstock

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

The researchers demonstrated that these coronavirus disease 2019 (COVID-19) drugs can be effective against SARS-CoV-2 variants resistant to nirmatrelvir and vice versa.

Background

Paxlovid, whose active component is nirmatrelvir, is a SARS-CoV-2 Mpro inhibitor widely used as a COVID-19 drug. However, scientists are concerned that, like other antivirals and vaccines, SARS-CoV-2 might also give rise to new variants with the potential to resist nirmatrelvir. Several studies have already found multiple candidate nirmatrelvir-resistance mutations.

Therefore, while there is an urgent need to assess the potential impact of these mutations, researchers are also actively working to develop novel Mpro-inhibiting drugs with varying drug resistance mechanisms.

Multiple single amino acid substitutions, e.g., T21I, in SARS-CoV-2 variants show insignificant resistance to all three drugs, namely, nirmatrelvir, ensitrelvir, or FB2001. M49L and M49I confer selective resistance to ensitrelvir, whereas A173V confers the same to nirmatrelvir. Similarly, ∆P168 elicits comparable resistance against ensitrelvir, or FB2001, and synergistic resistance to nirmatrelvir in combination with A173V.

Other mutations also confer resistance against these drugs. For instance,  L167F and S144A show the most resistance to ensitrelvir, followed by nirmatrelvir and FB2001. Contrastingly, E166V, and E166V with L50F trigger a higher resistance to nirmatrelvir, followed by ensitrelvir. However, its resistance to the FB2001 drug was extremely low.

About the study

In the present study, researchers used an expanded panel of Mpro single and double mutants to determine resistance profiles of nirmatrelvir, ensitrelvir (Xocova), and FB2001, a potential next-generation COVID-19 drug. Further, they used a gain-of-signal system as a quantitative metric for Mpro functionality. With an evolution and structure-guided approach, this assay characterized candidate nirmatrelvir- and ensitrelvir-resistance mutations in living cells.

The gain-of-signal system uses a higher expression of wildtype SARS-CoV-2 Mpro for cleaving multiple substrates in cells, including the one needed for ribonucleic acid polymerase (RNAPol) II-dependent gene expression. Any genetic mutation phenocopy the chemical dose responsiveness of this system using the Src-Mpro-Tat-Luc reporter, resulting in low to high luminescence. The assay used Mpro variant constructs and displayed a range of luminescence levels, which (in the absence of a drug) indicated normal, weakly compromised, and strongly compromised Mpro activity.

Results

Consistent with in vivo drug resistance studies using animal models, the gain of cell assay results suggested that several Mpro variants could confer limited drug resistance with minimal loss in Mpro functionality and, subsequently, higher viral fitness. Contrastingly, those with E166V mutations required suppressor mutations (e.g., L50F) to restore Mpro function for sufficient SARS-CoV-2 replication. Regardless of the molecular mechanism, all three drugs, nirmatrelvir, ensitrelvir, and FB2001, displayed distinct resistance mechanisms, which researchers called “fingerprints.”

In addition, FB2001 might confer a higher resistance barrier because the researchers noted that none of the Mpro variants tested conferred strong resistance to this drug. Studies have shown that patients suffer from bona fide resistance or Paxlovid rebound. With appropriate formulations, ensitrelvir and FB2001 might be effective in such cases.

Conclusions

To conclude, the gain-of-signal cell-based assay remarkably recapitulated the findings from studies using replication-competent SARS-CoV-2 and appears to be a safe and quick method for drug resistance assessments.

As more SARS-CoV-2 variants emerge, expanding this assay's variant panel could help assess drug-resistance mechanisms (“fingerprints”) of next-generation Mpro -inhibiting drug candidates. This early profiling strategy would abate the risks of developing SARS-CoV-2 drugs susceptible to cross-resistance. In addition, it could help identify Mpro inhibitors most resistant to viral mutations.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, March 01). New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs. News-Medical. Retrieved on July 19, 2024 from https://www.news-medical.net/news/20230301/New-cell-based-assay-shown-to-rapidly-profile-drug-resistance-to-three-widely-used-SARS-CoV-2-main-protease-inhibiting-drugs.aspx.

  • MLA

    Mathur, Neha. "New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs". News-Medical. 19 July 2024. <https://www.news-medical.net/news/20230301/New-cell-based-assay-shown-to-rapidly-profile-drug-resistance-to-three-widely-used-SARS-CoV-2-main-protease-inhibiting-drugs.aspx>.

  • Chicago

    Mathur, Neha. "New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs". News-Medical. https://www.news-medical.net/news/20230301/New-cell-based-assay-shown-to-rapidly-profile-drug-resistance-to-three-widely-used-SARS-CoV-2-main-protease-inhibiting-drugs.aspx. (accessed July 19, 2024).

  • Harvard

    Mathur, Neha. 2023. New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs. News-Medical, viewed 19 July 2024, https://www.news-medical.net/news/20230301/New-cell-based-assay-shown-to-rapidly-profile-drug-resistance-to-three-widely-used-SARS-CoV-2-main-protease-inhibiting-drugs.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New brain targets for GLP1-based obesity drugs may reduce weight without nausea